Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q39374988

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

@en

Elacytarabine

@nl

type

Item

label

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

@en

Elacytarabine

@nl

prefLabel

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

@en

Elacytarabine

@nl

P1476

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

@en

P2093

Courtney D DiNardo

http://www.w3.org/2001/XMLSchema#string

Varsha V Gandhi

http://www.w3.org/2001/XMLSchema#string

P2860

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Potential mechanisms of resistance to cytarabine in AML patients.

P304

1073-1082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.130

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Farhad Ravandi

Susan O'Brien

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23902239

http://www.w3.org/2001/XMLSchema#string

P921

leukemia